BN Business News
Add your company to Business Communicator →

Business · 17/10/2026

AbbVie Presents Long-Term Data on SKYRIZI and RINVOQ for Inflammatory Bowel Disease at UEGW 2026

AbbVie showcased extensive long-term clinical and endoscopic results from its IBD research programs, highlighting the company's leadership in the field, with 20 scientific presentations featuring SKYRIZI (risankizumab) and RINVOQ (upadacitinib).

Source: PR NewswireOpen original release →